Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Davis Polk Advises Valeant Pharmaceuticals International, Inc. on Its $6.25 Billion Refinancing
Davis Polk advised Valeant Pharmaceuticals International, Inc. in connection with a refinancing transaction pursuant to…
Bristol-Myers Squibb Company $1.5 Billion Notes Offering
Davis Polk advised the joint book-running managers and representatives of the underwriters on an SEC-registered public…
Davis Polk Advises Auris Medical Holding AG on Its Offering of Common Shares and Warrants to Purchase Common Shares
Davis Polk advised Auris Medical Holding AG on its $10 million public offering of 10,000,000 of its common shares and 10,000…
Hermes Pardini R$763 Million Initial Public Offering
Davis Polk advised the joint bookrunners in connection with the initial public offering by Hermes Pardini and the selling…
Coherus BioSciences, Inc. Follow-On Offering
Davis Polk advised the joint book-running managers in connection with the $125 million public offering of common stock of…
Davis Polk Advises McKesson Corporation on $1 Billion Notes Offering by Change Healthcare
Davis Polk advised McKesson Corporation in connection with the offering of $1 billion aggregate principal amount of notes…
Jounce Therapeutics, Inc. Initial Public Offering
Davis Polk advised the lead book-running manager and representative of the underwriters in connection with its $101.9…
Davis Polk Advises Affimed on Its $18 Million Offering of Shares
Davis Polk advised Affimed N.V. on its $18 million public offering of 10,000,000 of its common shares. The underwriters have…
Davis Polk Successfully Represents Aetna in Patent Infringement Suit
Davis Polk represents Aetna Inc. and its subsidiaries ActiveHealth Management, Inc. and Medicity, Inc. in a patent…
Loxo Oncology, Inc. Common Stock Offering
Davis Polk advised the joint book-running managers in connection with a $138 million SEC-registered offering of 4,450,500…